Enterprise Value
144.7M
Cash
201.9M
Avg Qtr Burn
-27.18M
Short % of Float
3.87%
Insider Ownership
9.09%
Institutional Own.
81.51%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PRT543 (PRMT5 inhibitor) Details Myelofibrosis, Solid tumor/s, Myelodysplastic syndrome, Cancer | Phase 1 Data readout | |
PRT3645 (CDK4/6 inhibitor) Details Head and neck cancer, Glioblastoma, Non-small cell lung carcinoma, Breast cancer | Phase 1 Data readout | |
PRT3789 [SMARCA2 degrader] Details Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
PRT2527 (CDK9 inhibitor) Details Acute myeloid leukemia, Solid tumor/s, Hematologic malignancies | Phase 1 Data readout | |
PRT7732 [SMARCA2 degrader] Details Cancer, Non-small cell lung carcinoma | Phase 1 Initiation | |
PRT1419 (MCL1 inhibitor) Details Hematologic malignancies, B-cell malignancies, Relapsed/refractory acute myeloid leukemia, Solid tumor/s | Failed Discontinued | |
PRT811 (PRMT5 inhibitor) Details primary central nervous system lymphomas, Cancer, Glioblastoma | Failed Discontinued |